Vertex Pharmaceuticals Retained Earnings History
| VRTX Stock | USD 430.29 -4.81 -1.11% |
Retained Earnings | First Reported 1990-12-31 | Previous Quarter 12.4 B | Current Value 13.6 B | Quarterly Volatility 3.9 B |
Macro event markers
Latest Vertex Pharmaceuticals Retained Earnings Growth Pattern
| View | Last Reported 13.56 B | 10 Years Trend |
|
Retained Earnings |
| Timeline |
Retained Earnings Trend Statistics
Across 15 reporting periods, Vertex Pharmaceuticals' Retained Earnings registers a CV of 536.0%, signaling wide dispersion driven primarily by directional growth rather than instability. The linear fit (R² = 0.70) suggests a strong linear fit indicating consistent directional movement.| Arithmetic Mean | 1,289,201,353 | |
| Geometric Mean | 3,194,851,843 | |
| Coefficient Of Variation | 536.04 | |
| Mean Deviation | 5,827,716,692 | |
| Median | -1,852,978,000 | |
| Standard Deviation | 6,910,664,549 | |
| Sample Variance | 47757284.5T | |
| Range | 19.6B | |
| R-Value | 0.84 | |
| Mean Square Error | 15133223.4T | |
| R-Squared | 0.70 | |
| Significance | 0.000026 | |
| Slope | 1,147,373,600 | |
| Total Sum of Squares | 764116552.1T |
Vertex Pharmaceuticals Retained Earnings History
From 2012 to 2026, Vertex Pharmaceuticals' Retained Earnings is reported across 15 periods, starting at -3.5 B and most recently at 14.2 B.| 2026 | 14.2 B | ||
| 2025 | 13.6 B | ||
| 2024 | 9.6 B | ||
| 2023 | 10.1 B | ||
| 2022 | 6.5 B | ||
| 2021 | 3.2 B | ||
| 2020 | 858.7 M | ||
| 2019 | -1.9 B | ||
| 2018 | -3 B | ||
| 2017 | -5.1 B | ||
| 2016 | -5.4 B | ||
| 2015 | -5.3 B | ||
| 2014 | -4.7 B | ||
| 2013 | -4 B | ||
| 2012 | -3.5 B |
Correlation of Retained Earnings With Other Accounts
The correlation matrix for Vertex Pharmaceuticals' Retained Earnings quantifies historical co-movement with related accounts. These are observational relationships across available periods.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Retained Earnings Total Equity | 7.5 B | 7.9 B | |
| Total Revenue | 12.1 B | 12.7 B | |
| Gross Profit | 10.3 B | 10.8 B | |
| Other Operating Expenses | 7.3 B | 7.7 B | |
| Operating Income | 4.8 B | 5 B | |
| EBIT | 4.8 B | 5 B |
Methodology, Assumptions & Data Sources
This chart tracks Vertex Pharmaceuticals's Retained Earnings on a year-over-year basis. Vertex Pharmaceuticals has a current Retained Earnings of 13.56 B. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners. A high R-squared fit to a linear trend indicates that the directional pattern is statistically consistent. As a technology-driven company, Vertex Pharmaceuticals' Retained Earnings reflects ownership capital supporting the operating base.
Vertex Pharmaceuticals metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Professional analyst research is incorporated when coverage is available. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board